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Abstract
Background: The aim of the present study was to investigate the association between serum levels of matrix
metalloproteinase 11 (MMP-11) and responses to front-line chemotherapy and prognosis in advanced unresectable
gastric adenocarcinoma.
Methods: Clinical data concerning 86 patients with advanced gastric adenocarcinoma (stages III c to IV), treated in
Beijing Chao-Yang Hospital from 2005 to 2009, were reviewed retrospectively. Adenocarcinoma was confirmed by
pathology and patients received 5-fluorouracil-based front-line combination chemotherapy with third generation
chemotherapeutic agents including paclitaxel, docetaxel and oxaliplatin. The regimen was repeated every two to
three weeks, and the first evaluation was carried out after three cycles. The median cycle of chemotherapy was 6
(ranging from three to twelve cycles). Serum MMP-11 protein from the 86 patients was examined using enzyme-
linked-immunosorbent-assay (ELISA) prior to chemotherapy and after three cycles of chemotherapy. Serum samples
from healthy individuals were used as controls.
Results: The response rate (RR, complete response plus partial response) to chemotherapy in the 86 patients was
44.2% (38/86). The median TTP (time to progression) and overall survival (OS) in patients who responded to
chemotherapy were 6.0 and 10.0 months, respectively. The response rate to chemotherapy in patients with high
levels of serum MMP-11 (42.9%; 9/21) was similar to that in patients with low levels (44.6%; 29/65) (P = 0.935).
Patients with low serum levels of MMP-11 had a higher median survival time and 1-year survival rate than those
with high levels (11 months vs. 8 months, 50.2% vs. 21.7%, P = 0.017), although the TTP was comparable in all
patients, irrespective of serum MMP-11 level (P = 0.178). Serum MMP-11 levels were correlated with lymph node
metastasis (P = 0.006). Cox multivariate regression analysis demonstrated that the serum level of MMP-11 was an
independent prognostic factor for patients presenting with advanced gastric carcinoma.
Conclusions: Serum levels of MMP-11 in Chinese patients with advanced gastric carcinoma were not associated with
the response to front-line chemotherapy, but could play an important role in lymph node metastasis and prognosis.
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Background
Gastric cancer (GC) is the second most common cancer
world-wide, and the third leading cause of cancer-
related deaths in China. Although the most effective
treatment for GC is surgical resection, approximately
70% of patients presenting with GC have a locally
advanced and metastatic disease at the time of initial
diagnosis, precluding the option of surgical resection
[1]. Therefore, systemic cytotoxic chemotherapy is a
major therapeutic strategy for advanced gastric carci-
noma. The combination of third generation chemothera-
peutic agents including paclitaxel, docetaxel and
oxaliplatin with 5-fluorouracil have improved therapeu-
tic response rates and overall survival by approximately
20-30% and 4-6 months, respectively. However, this
treatment can result in clinically significant adverse
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administer the most effective treatment, there is a
requirement for more sensitive tumor markers than
those currently available.
Matrix metalloproteinases (MMPs) are a family of
zinc-dependent endopeptidases that mediate degradation
of components of the extracellular matrix [2]. They are
predominantly produced by stromal cells in response to
the presence of tumor cells [3]. MMP-11 is a member
of the MMP family that degrades ECM components and
may play a central role in the enhancement of tumor-
induced angiogenesis, cell migration, proliferation, apop-
tosis and connective tissue degradation [4,5]. MMP-11
differs from other MMPs, which are expressed as proen-
zymes and processed to active forms through proteolytic
cleavage activated extracellularly, indicating that MMP-
11 could have a unique role in tumor development and
progression [6]. Clinicopathological studies have demon-
strated that MMP-11 is an important factor in tumor
progression in various malignant tumors including pul-
monary cancer [7], head and neck carcinoma [8,9] and
breast carcinoma [10].
Previously, we demonstrated that MMP-11 serum
levels were significantly higher in patients suffering from
GC than in healthy individuals, and were correlated
with recurrence of GC. Zhao et al [11] demonstrated
that MMP-11 expression was associated with advanced-
stage and high-grade tumors, and correlated with
increased expression of IGF-1. Min et al [12] suggested
that IGF-1 receptor blockade could increase radiation
and chemotherapy-induced apoptosis in mice. The aim
of the present study was to investigate whether elevated
MMP-11 expression could predict responses to front-
line chemotherapy and prognosis of Chinese patients
with advanced gastric carcinoma.
Methods
Patient Selection
Eighty-six patients with histopathologically confirmed
advanced unresectable gastric adenocarcinoma (stages
III c to IV) from March 2005 to February 2009 in Beij-
ing Chao-Yang Hospital were studied retrospectively.
Eligibility for the study required patients to have an
Eastern Cooperative Oncology Group performance sta-
tus of 0 to 2, and available plasma and measurable
tumor focus evaluated by multi-detector spiral CT scan-
ning. Patients had received front-line chemotherapy for
at least three cycles and were observed for chemother-
apy responses and survival outcomes. Tumors were
staged according to the criteria of the American Joint
Committee on Cancer (AJCC) TNM stage classification,
sixth edition (2002) for Gastric Cancer. In accordance
with the RECIST guidelines [13], response to therapy
was categorized into four groups: complete response
(CR), partial response (PR), stable disease (SD) and pro-
gression of disease (PD), with CR and PR confirmed for
four weeks. For tumor response assessment, objective
responses after three cycles of treatment were evaluated
on the basis of computed tomography (CT) scans. Over-
all survival was calculated as the time from the begin-
ning of chemotherapy to death or the last follow-up.
The time to progression of disease was calculated from
the date that chemotherapy began to the date of tumor
progression. Twenty healthy volunteers were recruited
as a control group. There was no evidence of malig-
nancy on abdominal computed tomography examination
of these individuals, and results of physical and labora-
tory examinations were normal. Individuals were
excluded from the study if they did not give consent.
Specimen Collection
A total of 86 serum samples from patients with
advanced gastric carcinoma and 20 samples from
healthy individuals were obtained from the clinical
laboratory. Serum samples from patients were collected
in a fasting state early in the morning prior to front-line
chemotherapy and after three cycles. Venous blood sam-
ples were collected in plain tubes, allowed to clot for
one hour and centrifuged twice (2500 g) for 10 minutes
at 4°C to obtain serum. The serum was removed, ali-
quoted and stored at -70°C until required.
MMP-11 Assay
The concentration of MMP-11 protein was measured
with a commercially available sandwich enzyme-linked
immunoadsorbent assay kit based on monoclonal anti-
bodies (Adlitteram Diagnostic Laboratories. Inc). Each
sample was measured in duplicate. Serum samples from
patients and control subjects were incubated in microti-
ter plates. Distilled or deionized water was added to the
plates to be used as a blank control. Enzyme conjugate
reagent (50 μl) was added to each well, incubated for 60
min at 37°C and washed 5 times with distilled or deio-
nized water. Finally, 50 μl of color A and B reagents
were added to each well and incubated for 15 min. Stop
solution (50 μl) was placed in each well and mixed for
30 s. The color development was measured by absor-
bance at 450 nm using a microtiter plate reader. Accu-
rate sample concentrations of MMP-11 were
determined by comparing the specific absorbance with
those obtained from the standards plotted on a standard
curve.
Statistical analysis
Statistical analysis was carried out using the Chi-square
test, Fisher’s exact test, ANOVA and independent-sam-
ples t test. For all analyses, p < 0.05 was considered sta-
tistically significant. The 95% CI for hazard ratios and
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ing characteristic (ROC) curves were constructed by
plotting sensitivity vs. (1-specificity), and the areas
under the ROC curves (AUCs) were calculated. Kaplan-
Meier curves were compared for survival using the stan-
dard log-rank test. To make further analyses with
Kaplan-Meier curves possible, patients were split into
two groups, one comprising patients with elevated
MMP-11 protein and the other comprising patients
without elevated MMP-11. The cut-off for this categor-
ized variable was set at the 75th percentile of MMP-11
in the total group. SPSS software (version 15) was used
for statistical analysis.
Results
Patient Characteristics
Eighty-six patients with advanced gastric carcinoma
(stages III c to IV) who received palliative chemotherapy
were included in the current analyses. Among these
patients, 60 were male and 26 were female. The median
age was 51 years (ranging from 50-56 years). Twenty
three patients had well differentiated adenocarcinoma,
63 presented with poorly differentiated adenocarcinoma.
Histological differentiation determined that 54 patients
(62.8%) had intestinal type adenocarcinoma, 20 (23.2%)
had mucinous carcinoma and signet-ring cell carcinoma
was present in 12 patients (14.0%). Clinical details are
listed in Table 1. In the control group, 15 individuals
were male and five were female. The median age was 40
years (ranging from 37-42 years).
MMP-11 protein levels in sera of gastric carcinoma
The serum levels of MMP-11 protein were significantly
higher in patients with advanced gastric adenocarcinoma
(n = 86; median = 41.74 ng/ml; range from 10.43 to
97.37 ng/ml) than in controls (n = 20; median = 6.74
ng/ml; range from 5.71 to 8.56 ng/ml; p < 0.001). Using
ROC analysis, a cut-off level of MMP-11 protein at
14.38 ng/ml was associated with optimal sensitivity and
specificity of 94.1% and 93.7%, respectively, for diagno-
sis. ROC curve analysis is presented in Figure 1.
Correlation between MMP-11 protein levels and
clinicopathological characteristics
The relationship between MMP-11 protein levels and
patient clinicopathological parameters is summarized in
Table 1. Serum levels of MMP-11 protein were not cor-
related with patient age, sex, disease stage and grade of
differentiation. However, MMP-11 protein levels were
significantly higher in patients suffering with lymph
node metastasis, including 31 local and 4 distant lymph
node metastases, compared with peritoneal seeding and
internal organ metastasis (P = 0.002 and P = 0.029,
respectively).
Correlation between MMP-11 protein levels and
chemotherapy response
All patients had measurable tumor foci and received 5-
fluorouracil-based combination chemotherapy for at
least three cycles (Table 2). PR was achieved in 44.2%
(38/86) of patients, 25.6% (22/86) had SD and 30.2%
(26/86) experienced PD with a median duration of six
months and overall survival of ten months. MMP-11
serum levels were not correlated with the front-line che-
motherapy response (P = 0.182). Patients were divided
into two groups according to MMP-11 levels (75th per-
centile or higher, and lower than the 75th percentile). A
t o t a lo f2 1p a t i e n t s( 2 4 . 4 % )h a dh i g h e rM M P - 1 1l e v e l s
than the 62.09 ng/ml cut-off. Of these patients, 42.9%
(9/21) achieved PR, 28.6% (6/21) had SD and 28.5% (6/
21) experienced PD. These results were similar to the
44.6% (29/65) PR, 24.6% (16/65) SD and 30.8% (20/65)
PD evident in the low MMP-11 level group (P = 0.935).
MMP-11 levels were differently altered in PR and PD.
MMP-11 protein was lower than baseline in patients
demonstrating PR (median = 45.15 ng/ml, 95%CI:
35.79-62.09 vs. 44.12 ng/ml, 95%CI: 34.32-56.52; P =
0.147). However, it showed an elevated trend in those
with PD (median = 47.29 ng/ml, 95%CI: 36.05-53.73 vs.
50.52 ng/ml, 95%CI: 37.74-54.22; P = 0.297).
Correlation between MMP-11 levels and survival
The median follow-up time was 10.50 months (ranging
from 9.07 to 12.94 months); the median TTP, OS and
1-year survival were six months, ten months and 40.0%,
respectively. The median TTP time for patients with
low levels of MMP-11 was not significantly different
from patients with high levels (median = 6.0, range from
4.98 to 7.02 months vs. median = 5.0 months, range
from 3.28 to 6.72 months; P = 0.178, Figure 2). How-
ever, patients with low level MMP-11 protein had an
higher median survival time and 1-year survival rate
than those with high levels (11 vs. 8 months, 50.2% vs.
21.7%, P = 0.017, Figure 3) in a multivariate analysis
that considered MMP-11 level as an independent factor
of OS in advanced gastric carcinoma (HR = 2.618, 95%
CI 1.288-5.320, P = 0.018, Table 3).
Discussion
This study demonstrated that MMP-11 over-expression
was consistently detected in advanced gastric adenocar-
cinoma. MMP-11 serum levels in 86 cases of advanced
gastric adenocarcinoma were not associated with
responses to 5-fluorouracil-containing chemotherapy
and TTP as front-line chemotherapy. However, they
correlated with lymph node status and mOS. These data
suggest that MMP-11 could be involved in metastatic
dissemination and be regarded as an independent prog-
nostic factor of advanced gastric adenocarcinoma.
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development of new chemotherapy regimes, gastric car-
cinoma remains the third leading cause of cancer-related
deaths in China [14]. Previously, we demonstrated that
MMP-11 was a cancer-related protein and its over-
expression was consistently confirmed at mRNA and
protein levels in primary gastric adenocarcinoma tumors
compared with matched normal tissues. Currently, the
impact of MMP-11 on advanced gastric adenocarcinoma
is uncertain. The aim of the study was to evaluate the
associations between the expression of MMP-11 protein
in serum and response to front-line chemotherapy and
prognosis in advanced gastric adenocarcinoma. The
results demonstrate that serum MMP-11 levels are not
correlated with response to front-line chemotherapy, but
are correlated with lymph node status and mOS in
patients with advanced gastric adenocarcinoma.
MMPs have a broad spectrum of proteolytic activities
towards extracellular matrix (ECM) components, and are
believed to be involved in several biological processes
Table 1 MMP-11 Levels and Clinical Characteristics
Clinical data No. of Case (%) MMP-11 level P
-value
Mean ± SD (ng/ml)
NO. of patients 86
Gender
Male 60(69.8%) 45.76 ± 22.89 0.200
Female 26(30.2%) 38.79 ± 23.17
Age (yrs)
Median 51(50-56)
<65 63(73.3%) 43.40 ± 22.76 0.166
≥65 23(26.7%) 50.79 ± 21.96
Differentiation
G1, G2 23(26.7%) 48.56 ± 23.30 0.235
G3 63(73.3%) 41.86 ± 22.90
Histology
Intestinal type adenocarcinoma 54(62.8%) 44.22 ± 23.92
Mucinous carcinoma 20(23.2%) 45.89 ± 17.99 0.527
Signet-ring cell carcinoma 12(14.0%) 53.44 ± 23.80
ECOG
0-1 68(79.1%) 46.14 ± 21.40 0.610
2 18(20.9%) 43.33 ± 26.49
Disease stage
III c 26(30.2%) 43.22 ± 31.02 0.288
IV 60(69.8%) 48.45 ± 23.57
Metastasis site
Lymph node 35(40.7%)
*# 52.55 ± 24.72
Peritoneum 21(24.4%)
# 33.44 ± 14.46 0.006 (*0.029,
#0.002)
Internal organs 30(34.9%) * 40.42 ± 22.74
Chemotherapy cycles 377
Median 6.00(3.00-12.00)
mTTP (m)
Median 6.00(5.29-6.71)
mOS (m)
Median 10.00(8.51-11.50)
Response
PR 38(44.2% ) 46.85 ± 24.92 0.182
SD 22(25.6% ) 37.34 ± 19.95
PD 26(30.2% ) 48.97 ± 20.23
Abbreviations: PR, partial response; SD, stable disease; PD, progression of disease. Analysis of the difference between groups using analysis of variance (ANOVA).
Where differences were identified, further analysis (between pairs of groups, with respective pairs for each molecule marked with *and *) was performed using
Scheffe (95% confidence interval (CI))
Yan et al. BMC Cancer 2011, 11:151
http://www.biomedcentral.com/1471-2407/11/151
Page 4 of 7including embryo implantation and morphogenesis, cell
migration, metastasis, tumor invasion and wound healing
[15,16]. MMP-11 over-expression has been demonstrated
in human cancers including oral cancer [17,18], desmoid
tumors [19], non-small cell lung cancer [20] and esopha-
geal adenocarcinoma [21]. Furthermore, increased MMP-
11 gene expression is correlated with increased aggressive-
ness of tumors and a poor clinical outcome [22,23]. Clini-
cal trials have demonstrated that a high level of MMP-11
expression is correlated with a lower survival rate among
patients with breast, non-small cell lung cancer and colon
cancer [24,25]. Deng et al [6] reported that the BGC823
cell-line silenced MMP-11 expression and significantly
inhibited cell proliferation and colony formation in soft
agar medium and tumorigenicity in nude mice. The same
authors also demonstrated that MMP-11 promoted the
proliferation, invasion and tumorigenicity of the AGS cell
line. Such experimental evidence has provided a causative
role for MMP-11 protein during tumor progression. This
study is the first to identify a correlation between MMP-
11 expression and outcome in advanced gastric adenocar-
cinoma patients. In this study, MMP-11 protein levels
appeared to correlate with invasion potential and high
levels were related to the extent of lymph node metastasis
in GC (P = 0.006), similar to data reported for other malig-
nancies [26]. Moreover, this study demonstrates that
patients with high level MMP-11 expression had a shorter
survival time than patients with low levels of MMP-11. In
other words, the findings indicate that MMP-11 protein is
an independent prognostic factor for patients with
advanced gastric adenocarcinoma. As has been reported
previously in breast and head and neck cancer, there were
no obvious associations among the degree of tumor differ-
entiation, MMP-11 protein level, sex and age.
There was no statistical difference between MMP-11
levels with mTTP and chemotherapy response. Potential
reasons for this could be: (1) there were no differences in
terms of the effects of MMP-11 on mTTP and che-
motherapy response in advanced gastric adenocarcinoma;
Figure 1 Serum MMP-11 ROC curve. Receiver operating
characteristic (ROC) curve of serum MMP-11 concentration: AUC =
0.989, P < 0.001.
Table 2 Chemotherapy Regimens Used in AGC
Chemotherapy regimen Number of patients
Paclitaxel, cisplatin, 5-fluorouracil 37
Paclitaxel, 5-fluorouracil 21
Oxaliplatin, 5-fluorouracil 18
Docetaxel, 5-fluorouracil 10
Figure 2 TTP curves of high level MMP-11 compared with low
level MMP-11.
Figure 3 Overall survival curves for high level MMP-11
compared with low level MMP-11.
Yan et al. BMC Cancer 2011, 11:151
http://www.biomedcentral.com/1471-2407/11/151
Page 5 of 7(2) the number of cases studied in the current research
was not large enough. The OS in the present study was
different from the results reported for the V325 trial [27].
Possible explanations include the fact that this was a ret-
rospective study; several factors could influence survival.
The chemotherapy regimens used in the present study
differed in some ways from that used in the V325 trial,
which could affect OS.
Conclusions
This study suggests that serum levels of MMP-11 pro-
tein in Chinese patients with advanced GC are not asso-
ciated with responses to front-line chemotherapy.
However, MMP-11 could have a role in lymph node
metastasis and could potentially be an independent fac-
tor for prognosis.
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